Developer docs
API playgroundTry for free, no card

Search company profiles

Spectrum Pharmaceuticals

Full company profile

uuid000222j

Namestring
Spectrum Pharmaceuticals
Legal namestring
Spectrum Pharmaceuticals Inc.
Websiteurl
sppirx.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company founded in 1987 that developed and commercialized oncology and hematology therapeutics. Its core product portfolio centered on ROLVEDON (eflapegrastim), a commercial-stage product whose launch was funded in 2022, alongside two investigational assets, Rolontis and poziotinib, both governed by licensing arrangements with South Korea-based Hanmi Pharmaceutical. The company's competitive positioning rested on late-stage oncology drug development, with portfolio expansion historically executed through acquisitions such as Talon Therapeutics (2013) and Allos Therapeutics (2012).

Operationally, Spectrum ran with 101–250 employees and followed a classic specialty-pharma business model: advance molecules through FDA-regulated clinical development, secure approval, and commercialize either through a focused US sales force or via licensing partners for ex-US markets. Revenue, where generated, came from product sales and licensing/royalty streams; however, the financial data as supplied appears corrupted at the unit level, and the company's multi-year EBITDA and net income figures indicate persistent operating losses consistent with a development-stage and early-commercial biotech. The September 2022 debt facility from SLR Capital Partners (up to $65 million, milestone-tranched) and the January 2022 $20 million equity investment from Hanmi Pharmaceutical were explicitly designed to fund the ROLVEDON launch and extend cash runway through 2024.

In mid-2023 Spectrum was acquired by Assertio, a strategic acquirer focused on pain and neurology therapeutics, with Spectrum shareholders receiving a combination of cash and stock. The transaction effectively took Spectrum private, ended its Nasdaq listing (ticker SPPI), and folded its oncology assets into Assertio's broader portfolio. As a result, Spectrum no longer operates as an independent company, and any forward-looking investment thesis must be evaluated through the lens of its parent, Assertio Holdings (which itself was announced in May 2026 as being acquired by Zydus Worldwide DMCC).

Short descriptiontext

Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company (founded 1987) that developed and commercialized oncology and hematology drugs including ROLVEDON, Rolontis, and poziotinib; it served US prescribers and partnered with Hanmi Pharmaceutical for ex-US markets before being acquired by Assertio in mid-2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLake Forest, United States
HQ citystring
Lake Forest
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, hematology drugs, biopharmaceutical development, cancer treatment drugs, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ROLVEDON
Description

Commercial product launched by Spectrum Pharmaceuticals, a drug for which the company secured financing for commercial launch

biospace.com
Core offering1 text field

Spectrum Pharmaceuticals developed and commercialized oncology and hematology therapeutics, including Rolvedon (eflapegrastim), Rolontis, and poziotinib. The company focused on late-stage drug development for cancer treatment, operating in the US biopharmaceutical market. Its products were sold through specialty distribution and hospital channels for use in cancer care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Spectrum Pharmaceuticals was a Nasdaq-listed biotech focused on late-stage oncology drug development. The company developed drugs including Rolvedon (ROLVEDON), Rolontis, and poziotinib. Spectrum was acquired by Assertio in mid-2023 and ceased independent operations. No product portfolio details are available from current accessible sources.

Product and service3 records
1ROLVEDON (eflapegrastim)
CategoryOncology Pharmaceutical
2Rolontis (eflapegrastim-xnst)
CategoryOncology Pharmaceutical
3Poziotinib
CategoryOncology Pharmaceutical
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Small clinical-stage oncology biotech; comparable in scale and late-stage oncology drug development model.

TypeDirect peer
Description

Specialty biopharma with significant oncology and hematology franchise; comparable in therapeutic focus, branded specialty drug development model, and late-stage oncology pipeline strategy.

TypeDirect peer
Description

Small-cap specialty pharma focused on oncology and critical care injectables; directly comparable in scale, therapeutic focus on oncology supportive care, and branded specialty drug positioning.

4MEI Pharma
TypeDirect peer
Description

Clinical-stage oncology biotech developing hematology and solid tumor therapies; comparable in late-stage oncology pipeline profile and small-cap specialty focus.

TypeDirect peer
Description

Private specialty pharma focused on oncology supportive care and cancer therapeutics; directly comparable to Spectrum's Rolvedon franchise in supportive care market.

TypeDirect peer
Description

Clinical-stage oncology biotech developing cancer therapies; comparable as a small-cap, late-stage oncology drug developer with similar pipeline risk profile.

TypeDirect peer
Description

Small-cap oncology biotech developing hematology and solid tumor therapies; comparable in scale, oncology-only focus, and late-stage clinical pipeline model.

TypeDirect peer
Description

Oncology-focused biotech with supportive care franchise (COSELA); highly comparable to Spectrum's Rolvedon positioning in chemotherapy-induced neutropenia supportive care.

TypeBroad incumbent
Description

Large established biopharma with deep oncology franchise and supportive care biologics (including pegfilgrastim via Neulasta); broader portfolio player whose oncology assets overlap with Spectrum's Rolvedon market.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Major oncology incumbent with broad hematology and solid tumor franchise; relevant comparable for Spectrum's oncology/hematology therapeutic positioning at scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spectrum Pharmaceuticals

Oncology Pharmaceuticalssppirx.com

Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company (founded 1987) that developed and commercialized oncology and hematology drugs including ROLVEDON, Rolontis, and poziotinib; it served US prescribers and partnered with Hanmi Pharmaceutical for ex-US markets before being acquired by Assertio in mid-2023.

What Spectrum Pharmaceuticals does

Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company founded in 1987 that developed and commercialized oncology and hematology therapeutics. Its core product portfolio centered on ROLVEDON (eflapegrastim), a commercial-stage product whose launch was funded in 2022, alongside two investigational assets, Rolontis and poziotinib, both governed by licensing arrangements with South Korea-based Hanmi Pharmaceutical. The company's competitive positioning rested on late-stage oncology drug development, with portfolio expansion historically executed through acquisitions such as Talon Therapeutics (2013) and Allos Therapeutics (2012).

Operationally, Spectrum ran with 101–250 employees and followed a classic specialty-pharma business model: advance molecules through FDA-regulated clinical development, secure approval, and commercialize either through a focused US sales force or via licensing partners for ex-US markets. Revenue, where generated, came from product sales and licensing/royalty streams; however, the financial data as supplied appears corrupted at the unit level, and the company's multi-year EBITDA and net income figures indicate persistent operating losses consistent with a development-stage and early-commercial biotech. The September 2022 debt facility from SLR Capital Partners (up to $65 million, milestone-tranched) and the January 2022 $20 million equity investment from Hanmi Pharmaceutical were explicitly designed to fund the ROLVEDON launch and extend cash runway through 2024.

In mid-2023 Spectrum was acquired by Assertio, a strategic acquirer focused on pain and neurology therapeutics, with Spectrum shareholders receiving a combination of cash and stock. The transaction effectively took Spectrum private, ended its Nasdaq listing (ticker SPPI), and folded its oncology assets into Assertio's broader portfolio. As a result, Spectrum no longer operates as an independent company, and any forward-looking investment thesis must be evaluated through the lens of its parent, Assertio Holdings (which itself was announced in May 2026 as being acquired by Zydus Worldwide DMCC).

Spectrum Pharmaceuticals firmographics

Firmographics
Name
Spectrum Pharmaceuticals
Legal name
Spectrum Pharmaceuticals Inc.
Website
https://sppirx.com
Company type
Private
Founded year
2002
Operating status
Acquired
Headcount range
101–250 employees
Short description
Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company (founded 1987) that developed and commercialized oncology and hematology drugs including ROLVEDON, Rolontis, and poziotinib; it served US prescribers and partnered with Hanmi Pharmaceutical for ex-US markets before being acquired by Assertio in mid-2023.
Ownership category
akta.pro rank

Spectrum Pharmaceuticals industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Hematology drugs
  • Biopharmaceutical development
  • Cancer treatment drugs
  • Specialty pharmaceuticals

Where Spectrum Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Lake Forest
HQ country
United States
HQ region
North America

Markets served

Spectrum Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Spectrum Pharmaceuticals product offering

Product offering

Core offering

Spectrum Pharmaceuticals developed and commercialized oncology and hematology therapeutics, including Rolvedon (eflapegrastim), Rolontis, and poziotinib. The company focused on late-stage drug development for cancer treatment, operating in the US biopharmaceutical market. Its products were sold through specialty distribution and hospital channels for use in cancer care.

Product overview

Spectrum Pharmaceuticals was a Nasdaq-listed biotech focused on late-stage oncology drug development. The company developed drugs including Rolvedon (ROLVEDON), Rolontis, and poziotinib. Spectrum was acquired by Assertio in mid-2023 and ceased independent operations. No product portfolio details are available from current accessible sources.

Differentiator

Problem solved

Functional benefit

Brands

  • ROLVEDON: Commercial product launched by Spectrum Pharmaceuticals, a drug for which the company secured financing for commercial launch

Products and services

  • ROLVEDON (eflapegrastim)
  • Rolontis (eflapegrastim-xnst)
  • Poziotinib

Companies that use Spectrum Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Spectrum Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Spectrum Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Spectrum Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Salarius Pharmaceuticals: Small clinical-stage oncology biotech; comparable in scale and late-stage oncology drug development model.
  • Jazz Pharmaceuticals: Specialty biopharma with significant oncology and hematology franchise; comparable in therapeutic focus, branded specialty drug development model, and late-stage oncology pipeline strategy.
  • Eagle Pharmaceuticals: Small-cap specialty pharma focused on oncology and critical care injectables; directly comparable in scale, therapeutic focus on oncology supportive care, and branded specialty drug positioning.
  • MEI Pharma: Clinical-stage oncology biotech developing hematology and solid tumor therapies; comparable in late-stage oncology pipeline profile and small-cap specialty focus.
  • Helsinn Group: Private specialty pharma focused on oncology supportive care and cancer therapeutics; directly comparable to Spectrum's Rolvedon franchise in supportive care market.
  • Aprea Therapeutics: Clinical-stage oncology biotech developing cancer therapies; comparable as a small-cap, late-stage oncology drug developer with similar pipeline risk profile.
  • Cyclacel Pharmaceuticals: Small-cap oncology biotech developing hematology and solid tumor therapies; comparable in scale, oncology-only focus, and late-stage clinical pipeline model.
  • G1 Therapeutics: Oncology-focused biotech with supportive care franchise (COSELA); highly comparable to Spectrum's Rolvedon positioning in chemotherapy-induced neutropenia supportive care.

Broad incumbents

  • Amgen: Large established biopharma with deep oncology franchise and supportive care biologics (including pegfilgrastim via Neulasta); broader portfolio player whose oncology assets overlap with Spectrum's Rolvedon market.
  • Bristol-Myers Squibb: Major oncology incumbent with broad hematology and solid tumor franchise; relevant comparable for Spectrum's oncology/hematology therapeutic positioning at scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Spectrum Pharmaceuticals social profiles

Digital presence

Spectrum Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spectrum Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Spectrum Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spectrum Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectrum Pharmaceuticals

What does Spectrum Pharmaceuticals do?

Spectrum Pharmaceuticals developed and commercialized oncology and hematology therapeutics, including Rolvedon (eflapegrastim), Rolontis, and poziotinib. The company focused on late-stage drug development for cancer treatment, operating in the US biopharmaceutical market. Its products were sold through specialty distribution and hospital channels for use in cancer care.

Is Spectrum Pharmaceuticals a public or private company?

Spectrum Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Spectrum Pharmaceuticals founded?

Spectrum Pharmaceuticals was founded in 2002. It employs 101 to 250 people.

Where is Spectrum Pharmaceuticals based?

Spectrum Pharmaceuticals is headquartered in Lake Forest, United States, in the North America region.

Who are Spectrum Pharmaceuticals's main competitors?

Direct peers on record are Salarius Pharmaceuticals, Jazz Pharmaceuticals, Eagle Pharmaceuticals, MEI Pharma, Helsinn Group, Aprea Therapeutics, Cyclacel Pharmaceuticals and G1 Therapeutics. Broad incumbents are Amgen and Bristol-Myers Squibb.

Does Spectrum Pharmaceuticals have an API?

No public API is recorded for Spectrum Pharmaceuticals.

What industry is Spectrum Pharmaceuticals in?

Spectrum Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSSpectrum Pharmaceuticals stock (US8485291018): where the cancer drug specialist stands after the acqSpectrum Pharmaceuticals, a Nasdaq-listed biotech focused on late-stage oncology drug development, was acquired by Assertio in mid-2023 and effectively disappeared from standalone trading. The deal gave Spectrum shareholders a mix of cash and stock, folding its assets into Assertio's broader pain and neurology portfolio as part of Assertio's strategy to diversify revenue. The article examines why the Spectrum Pharmaceuticals case remains relevant for US investors as a reference point for biotech M&A dynamics, risk transfer, and the evolving balance between independent development and consolidation in specialty oncology.Digital JournalPharmaceutical innovator’s quality systems reshape industry standards for drug developmentRamakrishna Sesham has developed enterprise-scale quality and compliance systems that support pharmaceutical development and regulatory approval processes worldwide. His work involves implementing frameworks for clinical, manufacturing, and regulatory operations at companies such as Astellas Pharma, Spectrum Pharmaceuticals, and Baxter Healthcare.openPR.comLiposome Drug Delivery Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | Spectrum Pharmaceuticals, Inc., Astellas Pharma Inc, Gilead Sciences Inc, Celsion Corporation, IpDataM Intelligence forecasts the liposome drug delivery market to grow at a 7% CAGR from 2024 to 2031. Key developments include Halozyme's $900M acquisition of Elektrofi and Pfizer's targeted liposomal system. North America holds the largest regional share.PR NewswireCLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025Berger Montague PC announced a September 24, 2025 deadline for Spectrum Pharmaceuticals (NASDAQ: SPPI) investors to seek appointment as lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased shares between March 17, 2022 and September 22, 2022. The lawsuit alleges Spectrum made false or misleading statements regarding its Pinnacle Study involving poziotinib, an experimental drug for certain lung cancer patients. Spectrum shares were subsequently delisted following the company's merger with Assertio Holdings, Inc.PR NewswireSpectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 2-DAY DEADLINE in Securities Lawsuit- Hagens BermanA New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action lawsuit, with a new deadline of September 24, 2025, after the previously appointed lead plaintiff was disqualified on August 4, 2025. The lawsuit, Christiansen v. Spectrum Pharmaceuticals, Inc., et al., alleges that Spectrum repeatedly misled investors about the success of its cancer treatment drug poziotinib, causing its share price to plummet more than 37% when the FDA's concerns over clinical trial results became public during the Class Period (March 17, 2022 – September 22, 2022). Assertio Holdings (ASRT) acquired Spectrum Pharmaceuticals in July 2023, making investors who received ASRT shares eligible to participate in the class action as potential lead plaintiffs.PR NewswireSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm announced a class action lawsuit against Spectrum Pharmaceuticals, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements about the results of its Pinnacle Study of poziotinib, a potential lung cancer treatment. Investors who purchased the company's securities between March 17, 2022 and September 22, 2022 are being sought to participate in the lawsuit before the September 24, 2025 deadline. The class has not yet been certified, and the complaint alleges that when the market learned the truth about the study results, investors suffered damages.PR NewswireSPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitRosen Law Firm reminds Spectrum Pharmaceuticals investors of a September 24, 2025 lead plaintiff deadline for a securities fraud class action. The lawsuit alleges false statements about the PINNACLE Study, a clinical trial for poziotinib. Investors with losses over $100K may lead the suit.PR NewswireSpectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 4-DAY DEADLINE in Securities Lawsuit- Hagens BermanA New York federal court re-opened the lead-plaintiff process in the Spectrum Pharmaceuticals securities class action, setting a new deadline of September 24, 2025. The case alleges the company misled investors about its cancer drug, causing a share-price drop of over 37%. Investors who acquired Spectrum shares during the class period may be eligible to represent the class.GlobeNewswireSPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before SeptBragar Eagel & Squire announced a class action lawsuit against Spectrum Pharmaceuticals, alleging false statements about its Pinnacle Study of poziotinib for lung cancer. Investors who bought shares between March 17 and September 22, 2022, have until September 24, 2025, to apply to be lead plaintiff.PR NewswireSpectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit- Hagens BermanA New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals securities class action, with a new deadline of September 24, 2025, following the disqualification of the previously appointed lead plaintiff on August 4, 2025. The lawsuit alleges that Spectrum Pharmaceuticals made misleading statements about its cancer drug poziotinib's efficacy, causing the company's share price to drop more than 37% when FDA concerns about clinical trial results became public during the class period of March 17, 2022 to September 22, 2022. Assertio Holdings acquired Spectrum Pharmaceuticals in July 2023, and investors who received ASRT shares in that transaction may be eligible to serve as lead plaintiff in the case, which has already survived a motion to dismiss.